Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers

Antiviral Therapy

Volumn 15, Issue 8, 2010, Pages 1141-1149

  Eide, Kathleen ^a   Moerdyk Schauwecker, Megan ^a   Stein, David A ^b   Bildfell, Rob ^a   Koelle, David M ^c   Jin, Ling ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTISENSE PEPTIDE CONJUGATED PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; ANTIVIRUS AGENT; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN 0; IMMEDIATE EARLY PROTEIN 27; MESSENGER RNA; MORPHOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENE EXPRESSION; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; IMMEDIATE EARLY GENE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS PLAQUE; VIRUS REPLICATION;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; IMMEDIATE-EARLY PROTEINS; MICE; MICE, INBRED BALB C; MORPHOLINES; PEPTIDES; RECURRENCE; SIGMODONTINAE; VERO CELLS; VIRAL PROTEINS; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 78650974057     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1694     Document Type: Article

References (25)

1. Xu F, Markowitz LE, Gottlieb SL, Berman SM. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. Am J Obstet Gynecol 2007; 196:43.e1-43.e6
2. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296:964-973.
3. Roizman B, Knipe DM. Herpes simplex viruses and their replication. In Knipe DM, Howley PM (Editors). Fields Virology. 4th ed. Philadelphia: Lippincott, Williams and Wilkins 2001; pp. 2399-2459.
4. Kim HN, Meier A, Huang ML, et al. Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men. J Infect Dis 2006; 194:420-427.
5. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000; 342:844-850.
6. Wolff MH, Schmitt J, Rahaus M, Dudda H, Hatzmann W. Clinical and subclinical reactivation of genital herpes virus. Intervirology 2002; 45:20-23.
7. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997; 7:187-195.
8. Stein D, Foster E, Huang SB, Weller D, Summerton J. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 1997; 7:151-157.
9. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 2004; 15:290-299.
10. Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol 2005; 79:4599-4609.
11. Stein DA. Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers. Curr Pharm Des 2008; 14:2619-2634.
12. Zhang YJ, Wang KY, Stein DA, et al. Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers. Antiviral Res 2007; 73:12-23.
13. Zhang YJ, Bonaparte RS, Patel D, Stein DA, Iversen PL. Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus. Mol Cancer Ther 2008; 7:712-720.
14. Moerdyk-Schauwecker M, Stein DA, Eide K, et al. Inhibition of HSV-1 ocular infection with morpholino oligomers targeting ICP0 and ICP27. Antiviral Res 2009; 84:131-141.
15. Czartoski T, Liu C, Koelle DM, Schmechel S, Kalus A, Wald A. Fulminant, acyclovir-resistant, herpes simplex virus type 2 hepatitis in an immunocompetent woman. J Clin Microbiol 2006; 44:1584-1586.
16. Abes S, Moulton HM, Clair P, et al. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 2006; 116:304-313. (Pubitemid 44827406)
17. Palliser D, Chowdhury D, Wang QY, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006; 439:89-94.
18. Yim KC, Carroll CJ, Tuyama A, et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol 2005; 79:14632-14639.
19. Chen J, Silverstein S. Herpes simplex viruses with mutations in the gene encoding ICP0 are defective in gene expression. J Virol 1992; 66:2916-2927.
20. Sandri-Goldin RM. The many roles of the regulatory protein ICP27 during herpes simplex virus infection. Front Biosci 2008; 13:5241-5256.
21. Zhe R, Mei-Ying Z, Kitazato K, et al. Effect of siRNA on HSV-1 plaque formation and relative expression levels of UL39 mRNA. Arch Virol 2008; 153:1401-1406.
22. Peyman A, Helsberg M, Kretzschmar G, Mag M, Grabley S, Uhlmann E. Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol Chem Hoppe Seyler 1995; 376:195-198.
23. Parr MB, Parr EL. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes. J Virol 1998; 72:2677-2685.
24. Mahjoub SB, Ganley JP, Misra RP, Langford MP. Isolation of a herpes simplex virus type 2 that is retinovirulent in mice. Curr Eye Res 1989; 8:687-695.
25. Gershengorn HB, Darby G, Blower SM. Predicting the emergence of drug-resistant HSV-2: new predictions. BMC Infect Dis 2003; 3:1.